<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Eur Acad Dermatol Venereol</journal-id><journal-id journal-id-type="iso-abbrev">J Eur Acad Dermatol Venereol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1468-3083</journal-id><journal-id journal-id-type="publisher-id">JDV</journal-id><journal-title-group><journal-title>Journal of the European Academy of Dermatology and Venereology</journal-title></journal-title-group><issn pub-type="ppub">0926-9959</issn><issn pub-type="epub">1468-3083</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28846163</article-id><article-id pub-id-type="pmc">5873455</article-id><article-id pub-id-type="doi">10.1111/jdv.14542</article-id><article-id pub-id-type="publisher-id">JDV14542</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles and Short Reports</subject><subj-group subj-group-type="heading"><subject>Oncology</subject></subj-group></subj-group></article-categories><title-group><article-title>Long&#x02010;term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30&#x02010;month analysis of the randomized phase 2 BOLT study</article-title><alt-title alt-title-type="left-running-head">Lear <italic>et&#x000a0;al</italic>.</alt-title></title-group><contrib-group><contrib id="jdv14542-cr-0001" contrib-type="author" corresp="yes"><name><surname>Lear</surname><given-names>J.T.</given-names></name><address><email>john.lear@cmft.nhs.uk</email></address><xref ref-type="aff" rid="jdv14542-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jdv14542-cr-0002" contrib-type="author"><name><surname>Migden</surname><given-names>M.R.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jdv14542-cr-0003" contrib-type="author"><name><surname>Lewis</surname><given-names>K.D.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jdv14542-cr-0004" contrib-type="author"><name><surname>Chang</surname><given-names>A.L.S.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jdv14542-cr-0005" contrib-type="author"><name><surname>Guminski</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jdv14542-cr-0006" contrib-type="author"><name><surname>Gutzmer</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jdv14542-cr-0007" contrib-type="author"><name><surname>Dirix</surname><given-names>L.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="jdv14542-cr-0008" contrib-type="author"><name><surname>Combemale</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="jdv14542-cr-0009" contrib-type="author"><name><surname>Stratigos</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="jdv14542-cr-0010" contrib-type="author"><name><surname>Plummer</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="jdv14542-cr-0011" contrib-type="author"><name><surname>Castro</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0011">
<sup>11</sup>
</xref><xref ref-type="author-notes" rid="jdv14542-note-1001">
<sup>[Link]</sup>
</xref></contrib><contrib id="jdv14542-cr-0012" contrib-type="author"><name><surname>Yi</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0012">
<sup>12</sup>
</xref><xref ref-type="author-notes" rid="jdv14542-note-1001">
<sup>[Link]</sup>
</xref></contrib><contrib id="jdv14542-cr-0013" contrib-type="author"><name><surname>Mone</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="jdv14542-cr-0014" contrib-type="author"><name><surname>Zhou</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="jdv14542-cr-0015" contrib-type="author"><name><surname>Trefzer</surname><given-names>U.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0013">
<sup>13</sup>
</xref></contrib><contrib id="jdv14542-cr-0016" contrib-type="author"><name><surname>Kaatz</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0014">
<sup>14</sup>
</xref></contrib><contrib id="jdv14542-cr-0017" contrib-type="author"><name><surname>Loquai</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0015">
<sup>15</sup>
</xref></contrib><contrib id="jdv14542-cr-0018" contrib-type="author"><name><surname>Kudchadkar</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0016">
<sup>16</sup>
</xref></contrib><contrib id="jdv14542-cr-0019" contrib-type="author"><name><surname>Sellami</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="jdv14542-cr-0020" contrib-type="author"><name><surname>Dummer</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="jdv14542-aff-0017">
<sup>17</sup>
</xref></contrib></contrib-group><aff id="jdv14542-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Manchester Academic Health Science Centre</named-content>
<institution>University of Manchester</institution>
<named-content content-type="city">Manchester</named-content>
<country country="GB">UK</country>
</aff><aff id="jdv14542-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Departments of Dermatology and Head and Neck Surgery</named-content>
<institution>The University of Texas MD Anderson Cancer Center</institution>
<named-content content-type="city">Houston</named-content>
<named-content content-type="country-part">TX</named-content>
<country country="US">USA</country>
</aff><aff id="jdv14542-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Division of Medical Oncology</named-content>
<institution>University of Colorado School of Medicine</institution>
<named-content content-type="city">Aurora</named-content>
<named-content content-type="country-part">CO</named-content>
<country country="US">USA</country>
</aff><aff id="jdv14542-aff-0004">
<label><sup>4</sup></label>
<institution>Stanford University School of Medicine</institution>
<named-content content-type="city">Redwood City</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff><aff id="jdv14542-aff-0005">
<label><sup>5</sup></label>
<institution>Royal North Shore Hospital</institution>
<named-content content-type="city">St Leonards</named-content>
<named-content content-type="country-part">NSW</named-content>
<country country="AU">Australia</country>
</aff><aff id="jdv14542-aff-0006">
<label><sup>6</sup></label>
<institution>Medizinische Hochschule Hannover</institution>
<named-content content-type="city">Hannover</named-content>
<country country="DE">Germany</country>
</aff><aff id="jdv14542-aff-0007">
<label><sup>7</sup></label>
<institution>Sint&#x02010;Augustinus Ziekenhuis</institution>
<named-content content-type="city">Antwerp</named-content>
<country country="BE">Belgium</country>
</aff><aff id="jdv14542-aff-0008">
<label><sup>8</sup></label>
<institution>Anti Cancer Institute, L&#x000e9;on B&#x000e9;rard</institution>
<named-content content-type="city">Lyon</named-content>
<country country="FR">France</country>
</aff><aff id="jdv14542-aff-0009">
<label><sup>9</sup></label>
<named-content content-type="organisation-division">Andreas Syggros Hospital</named-content>
<institution>University of Athens</institution>
<named-content content-type="city">Athens</named-content>
<country country="GR">Greece</country>
</aff><aff id="jdv14542-aff-0010">
<label><sup>10</sup></label>
<named-content content-type="organisation-division">Northern Centre for Cancer Care</named-content>
<institution>Freeman Hospital</institution>
<named-content content-type="city">Newcastle upon Tyne</named-content>
<country country="GB">UK</country>
</aff><aff id="jdv14542-aff-0011">
<label><sup>11</sup></label>
<institution>Novartis Pharma AG</institution>
<named-content content-type="city">Basel</named-content>
<country country="CH">Switzerland</country>
</aff><aff id="jdv14542-aff-0012">
<label><sup>12</sup></label>
<institution>Novartis Pharmaceuticals Corporation</institution>
<named-content content-type="street">East Hanover</named-content>
<named-content content-type="country-part">NJ</named-content>
<country country="US">USA</country>
</aff><aff id="jdv14542-aff-0013">
<label><sup>13</sup></label>
<institution>Dermatologikum Berlin</institution>
<named-content content-type="city">Berlin</named-content>
<country country="DE">Germany</country>
</aff><aff id="jdv14542-aff-0014">
<label><sup>14</sup></label>
<institution>University Hospital Jena</institution>
<named-content content-type="city">Jena</named-content>
<country country="DE">Germany</country>
</aff><aff id="jdv14542-aff-0015">
<label><sup>15</sup></label>
<institution>University Medical Center Mainz</institution>
<named-content content-type="city">Mainz</named-content>
<country country="DE">Germany</country>
</aff><aff id="jdv14542-aff-0016">
<label><sup>16</sup></label>
<institution>Winship Cancer Institute of Emory University</institution>
<named-content content-type="city">Atlanta</named-content>
<named-content content-type="country-part">GA</named-content>
<country country="US">USA</country>
</aff><aff id="jdv14542-aff-0017">
<label><sup>17</sup></label>
<named-content content-type="organisation-division">Universit&#x000e4;tsSpital Z&#x000fc;rich&#x02010;Skin Cancer Center</named-content>
<institution>University Hospital</institution>
<named-content content-type="city">Z&#x000fc;rich</named-content>
<country country="CH">Switzerland</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence: J.T. Lear. E&#x02010;mail: <email>john.lear@cmft.nhs.uk</email></corresp><fn fn-type="funding" id="jdv14542-note-1001"><p>Conflicts of interest</p><p>Dr Lear has served as a consultant or speaker for and received honoraria from Novartis Pharmaceuticals Corporation. Dr Migden has participated on advisory boards and received honoraria from Genentech, Inc.; Novartis Pharmaceuticals Corporation; and Eli Lilly and Company. Dr Lewis has received research funding paid to the institution from Novartis Pharmaceuticals Corporation. Dr Chang is a primary investigator for and has served as a consultant for and received research grant/funding paid to the institution from Novartis Pharmaceuticals Corporation. Dr Guminski has participated on advisory boards for Bristol&#x02010;Myers Squibb, Pfizer Inc. and Sanofi; received honoraria from Novartis Pharmaceuticals Corporation; and received travel support from Astellas and Bristol&#x02010;Myers Squibb. Dr Gutzmer has received research grants paid to the institution from Roche, Novartis Pharmaceuticals Corporation, Johnson &#x00026; Johnson and Pfizer Inc.; received honoraria from Roche, Bristol&#x02010;Myers Squibb, MSD, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Merck Serono, Almirall, Janssen, Amgen Inc., Galderma and Boehringer Ingelheim; and served as a consultant for Roche, Bristol&#x02010;Myers Squibb, MSD, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Almirall, LEO Pharma Inc., Amgen Inc. and Pfizer Inc. Dr Dirix has no conflict of interest to declare. Dr Combemale has no conflict of interest to declare. Dr Stratigos has received a research grant from Roche and Novartis Pharmaceuticals Corporation and received honoraria from LEO Pharma Inc., Meda Pharmaceuticals Inc. and Janssen&#x02010;Cilag. Dr. Plummer has participated on an advisory board and received honoraria from Astex, Roche, Bristol&#x02010;Myers Squibb, Vertex, Bayer, Pierre Faber, Novartis Pharmaceuticals Corporation and Clovis Oncology. Dr Castro was an employee of Novartis during the development of this manuscript and is currently an employee of Bristol&#x02010;Myers Squibb. Dr Yi was an employee of Novartis during the development of this manuscript. Dr Mone is an employee and stockholder of Novartis Pharmaceuticals Corporation. Dr Zhou is an employee of Novartis Pharmaceuticals Corporation. Dr Trefzer has been an advisor for and received honoraria from F. Hoffmann&#x02010;La Roche Ltd, participated on an advisory board and received honoraria from MSD, and has been a speaker and received honoraria from Novartis Pharmaceuticals Corporation. Dr Kaatz has participated on advisory boards and received honoraria from Roche, MSD, Novartis Pharmaceuticals Corporation, Bristol&#x02010;Myers Squibb and Janssen. Dr Loquai has served as a consultant for Bristol&#x02010;Myers Squibb, Roche, Novartis Pharmaceuticals Corporation, Amgen, BioNTech and MSD. Dr Kudchadkar has participated on an advisory board and received honoraria from Bristol&#x02010;Myers Squibb and Genentech, Inc. Dr Sellami is an employee and stockholder of Novartis Pharmaceuticals Corporation. Dr Dummer has received research funding from Novartis Pharmaceuticals Corporation, MSD, Bristol&#x02010;Myers Squibb, Roche and GlaxoSmithKline and has served as a consultant or participated on an advisory board for Novartis Pharmaceuticals Corporation, MSD, Bristol&#x02010;Myers Squibb, Roche, GlaxoSmithKline, Amgen and Takeda.</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2018</year></pub-date><volume>32</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/jdv.2018.32.issue-3</issue-id><fpage>372</fpage><lpage>381</lpage><history><date date-type="received"><day>14</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>07</day><month>8</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2018 European Academy of Dermatology and Venereology <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Journal of the European Academy of Dermatology and Venereology</italic> published by John Wiley &#x00026; Sons Ltd on behalf of European Academy of Dermatology and Venereology.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JDV-32-372.pdf"/><abstract id="jdv14542-abs-0001"><title>Abstract</title><sec id="jdv14542-sec-0001"><title>Background</title><p>Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult&#x02010;to&#x02010;treat populations, have had limited treatment options. Sonidegib, a hedgehog pathway inhibitor (HPI), was approved in laBCC based on results from the BOLT trial.</p></sec><sec id="jdv14542-sec-0002"><title>Objective</title><p>To evaluate long&#x02010;term efficacy and safety of sonidegib in laBCC and mBCC in the BOLT 18&#x02010; and 30&#x02010;month analyses.</p></sec><sec id="jdv14542-sec-0003"><title>Methods</title><p>BOLT (NCT01327053, ClinicalTrials.gov), a double&#x02010;blind phase 2 study, enrolled patients from July 2011 until January 2013. Eligible HPI&#x02010;treatment&#x02013;na&#x000ef;ve patients with laBCC not amenable to curative surgery/radiotherapy or mBCC were randomized 1&#x000a0;:&#x000a0;2 to sonidegib 200&#x000a0;mg (laBCC, <italic>n</italic>&#x000a0;=&#x000a0;66; mBCC, <italic>n</italic>&#x000a0;=&#x000a0;13) or 800&#x000a0;mg (laBCC, <italic>n</italic>&#x000a0;=&#x000a0;128; mBCC, <italic>n</italic>&#x000a0;=&#x000a0;23). Tumour response was assessed per central and investigator review.</p></sec><sec id="jdv14542-sec-0004"><title>Results</title><p>With 30&#x000a0;months of follow&#x02010;up, among patients treated with sonidegib 200&#x000a0;mg (approved dose), objective response rates were 56.1% (central) and 71.2% (investigator) in laBCC and 7.7% (central) and 23.1% (investigator) in mBCC. Tumour responses were durable as follows: median duration of response was 26.1&#x000a0;months (central) and 15.7&#x000a0;months (investigator) in laBCC and 24.0&#x000a0;months (central) and 18.1&#x000a0;months (investigator) in mBCC. Five patients with laBCC and three with mBCC in the 200&#x02010;mg arm died. Median overall survival was not reached in either population; 2&#x02010;year overall survival rates were 93.2% (laBCC) and 69.3% (mBCC). In laBCC, efficacy was similar regardless of aggressive or non&#x02010;aggressive histology. Sonidegib 200&#x000a0;mg continued to have a better safety profile than 800&#x000a0;mg, with lower rates of grade 3/4 adverse events (43.0% vs. 64.0%) and adverse events leading to discontinuation (30.4% vs. 40.0%).</p></sec><sec id="jdv14542-sec-0005"><title>Conclusion</title><p>Sonidegib continued to demonstrate long&#x02010;term efficacy and safety in these populations. These data support the use of sonidegib 200&#x000a0;mg per local treatment guidelines.</p></sec></abstract><funding-group><award-group><funding-source>Novartis Pharmaceuticals Corporation</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="10"/><word-count count="7124"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jdv14542</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.3 mode:remove_FC converted:28.03.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jdv14542-ntgp-0001"><fn fn-type="funding" id="jdv14542-note-1002"><p>Funding sources</p><p>This study was funded by Novartis Pharmaceuticals Corporation. Novartis Pharmaceuticals Corporation was involved in design and conduct of the study; collection, management, analysis and interpretation of data; preparation, review and approval of the manuscript; and decision to submit the manuscript for publication.</p></fn><fn id="jdv14542-note-1003"><p>Affiliation at the time the study was conducted. HC and TY are no longer affiliated with Novartis Pharmaceuticals.</p></fn></fn-group></notes></front><body><sec id="jdv14542-sec-0006"><title>Introduction</title><p>Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC) have historically had limited treatment options.<xref rid="jdv14542-bib-0001" ref-type="ref">1</xref> Surgery, the primary course of treatment for most BCCs, and radiotherapy are often not viable options in advanced BCC.<xref rid="jdv14542-bib-0001" ref-type="ref">1</xref>, <xref rid="jdv14542-bib-0002" ref-type="ref">2</xref>, <xref rid="jdv14542-bib-0003" ref-type="ref">3</xref> In recent years, hedgehog (Hh) pathway inhibitors (HPIs) were developed to block aberrant Hh signalling that is found in most sporadic BCCs; HPIs have demonstrated efficacy in patients with laBCC and those with mBCC.<xref rid="jdv14542-bib-0004" ref-type="ref">4</xref>, <xref rid="jdv14542-bib-0005" ref-type="ref">5</xref>, <xref rid="jdv14542-bib-0006" ref-type="ref">6</xref>, <xref rid="jdv14542-bib-0007" ref-type="ref">7</xref>, <xref rid="jdv14542-bib-0008" ref-type="ref">8</xref>, <xref rid="jdv14542-bib-0009" ref-type="ref">9</xref>, <xref rid="jdv14542-bib-0010" ref-type="ref">10</xref>, <xref rid="jdv14542-bib-0011" ref-type="ref">11</xref>, <xref rid="jdv14542-bib-0012" ref-type="ref">12</xref>, <xref rid="jdv14542-bib-0013" ref-type="ref">13</xref>
</p><p>Sonidegib (LDE225), which inhibits Hh signalling by targeting the Hh pathway component smoothened,<xref rid="jdv14542-bib-0006" ref-type="ref">6</xref> was approved (200&#x000a0;mg once daily) in the United States and Europe for the treatment of laBCC, in Australia for the treatment of laBCC and mBCC and in Switzerland for the treatment of advanced BCC that cannot be treated with curative surgery or radiotherapy.<xref rid="jdv14542-bib-0014" ref-type="ref">14</xref>, <xref rid="jdv14542-bib-0015" ref-type="ref">15</xref>, <xref rid="jdv14542-bib-0016" ref-type="ref">16</xref>, <xref rid="jdv14542-bib-0017" ref-type="ref">17</xref> These approvals were based on results from the pivotal phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) study (NCT01327053), in which the primary analysis was performed using data based on 6&#x000a0;months of follow&#x02010;up.<xref rid="jdv14542-bib-0008" ref-type="ref">8</xref>, <xref rid="jdv14542-bib-0009" ref-type="ref">9</xref> Here, we report long&#x02010;term efficacy and safety results from BOLT, with up to 30&#x000a0;months of follow&#x02010;up after the last patient was randomized.</p></sec><sec id="jdv14542-sec-0007"><title>Materials and methods</title><sec id="jdv14542-sec-0008"><title>BOLT study design and patients</title><p>BOLT is a randomized, double&#x02010;blind, phase 2 study conducted in 58 centres across 12 countries that assessed the efficacy and safety of sonidegib 200 and 800&#x000a0;mg once daily, as described previously.<xref rid="jdv14542-bib-0008" ref-type="ref">8</xref> Patients &#x02265;18&#x000a0;years of age with histologically confirmed disease, either laBCC not amenable to curative surgery or radiotherapy or mBCC, were eligible. Patients were required to have adequate organ function and a World Health Organization (WHO)<xref rid="jdv14542-bib-0018" ref-type="ref">18</xref> performance status &#x02264;2. Patients with previous HPI treatment were not eligible. Full inclusion and exclusion criteria were reported previously.<xref rid="jdv14542-bib-0008" ref-type="ref">8</xref>
</p><p>Patients were randomized 1&#x000a0;:&#x000a0;2 to 200 or 800&#x000a0;mg based on previous data suggesting that 800&#x000a0;mg would show better efficacy.<xref rid="jdv14542-bib-0007" ref-type="ref">7</xref> Randomization was performed using the central Interactive Response Technology system (Cenduit, Allentown, PA). Stratification of patients was based on disease type (laBCC vs. mBCC), histological subtype (aggressive vs. non&#x02010;aggressive) and geographic region. All patients and study personnel were blinded until the time of the primary analysis.</p><p>The study protocol was approved at each centre by independent ethics committee or institutional review board, and all patients provided written informed consent prior to enrolment.</p></sec><sec id="jdv14542-sec-0009"><title>Sonidegib treatment and assessments</title><p>Sonidegib capsules were taken orally on a once&#x02010;daily continuous schedule until disease progression, intolerable toxicity, withdrawal of patient consent, discontinuation at the discretion of the investigator, death or study termination. Tumour evaluations were conducted at baseline, during treatment and post&#x02010;treatment follow&#x02010;up (weeks 5 and 9, then every 8&#x000a0;weeks during year 1 and every 12&#x000a0;weeks thereafter), and at discontinuation using BCC&#x02010;modified Response Evaluation Criteria In Solid Tumors (mRECIST)<xref rid="jdv14542-bib-0008" ref-type="ref">8</xref>, <xref rid="jdv14542-bib-0009" ref-type="ref">9</xref> for laBCC and RECIST v1.1<xref rid="jdv14542-bib-0019" ref-type="ref">19</xref> for mBCC. mRECIST<xref rid="jdv14542-bib-0008" ref-type="ref">8</xref>, <xref rid="jdv14542-bib-0009" ref-type="ref">9</xref> is a stringent multimodal assessment tool that incorporates magnetic resonance imaging (MRI) per RECIST v1.1<xref rid="jdv14542-bib-0019" ref-type="ref">19</xref> [&#x02265;30% reduction in the sum of the longest diameters of target lesions required for a partial response (PR)], standard and annotated color photography per bidimensional WHO guidelines<xref rid="jdv14542-bib-0018" ref-type="ref">18</xref> (&#x02265;50% reduction in the sum of the products of perpendicular diameters of target lesions required for a PR), and histology in multiple biopsies surveying the lesion area to determine a composite overall response. Complete responses (CRs) and PRs had to be confirmed on repeat assessments separated by &#x02265;4&#x000a0;weeks. Fresh tumour biopsies were used to confirm CRs in the presence of confounding ulceration, cyst formation and/or scarring/fibrosis. An independent review committee re&#x02010;evaluated all central assessments for patients with laBCC.</p><p>In a prespecified analysis, responses were re&#x02010;evaluated in patients with laBCC using BCC&#x02010;RECIST&#x02010;like, less&#x02010;stringent criteria similar to those used in ERIVANCE, a phase 2 study of vismodegib.<xref rid="jdv14542-bib-0011" ref-type="ref">11</xref> Both mRECIST and BCC&#x02010;RECIST&#x02010;like integrate MRI per RECIST v1.1, standard and annotated color photography per WHO guidelines, and histology; however, the algorithm used to determine overall response for each is different: multiple scenarios exist for which the response is lower with mRECIST vs. BCC&#x02010;RECIST&#x02010;like (Table&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S1</xref>, Supporting Information).</p><p>Blood samples for pharmacokinetic (PK) assessments were collected from all patients through week 69; trough plasma concentrations were analysed at predose on weeks 1, 3, 5 and 9, then every 4&#x000a0;weeks through week 21 and every 12&#x000a0;weeks thereafter.</p><p>Adverse events (AEs) were monitored throughout the treatment period until 30&#x000a0;days following the last sonidegib dose according to Common Terminology Criteria for Adverse Events v4.03.<xref rid="jdv14542-bib-0020" ref-type="ref">20</xref>
</p></sec><sec id="jdv14542-sec-0010"><title>BOLT study outcomes</title><p>The primary study endpoint was objective response rate (ORR; proportion of patients with a best overall response of CR or PR) per central review. Secondary endpoints included ORR per investigator review; CR rate, duration of response (DOR) and progression&#x02010;free survival (PFS) per central and investigator review; overall survival (OS); and safety.</p></sec><sec id="jdv14542-sec-0011"><title>Statistical methods</title><p>Results were analysed based on two database cut&#x02010;offs: 11 July 2014 and 10 July 2015 (18 and 30&#x000a0;months after the last patient was randomized, respectively). ORR and CR rates were estimated with 95% CIs. Kaplan&#x02013;Meier nonparametric maximum likelihood estimates of median time and 95% CIs were estimated for DOR and PFS for each arm and by disease. Statistical comparisons of the 200&#x02010; and 800&#x02010;mg arms were not planned. Additional details on the statistical methods used in the study were published previously.<xref rid="jdv14542-bib-0008" ref-type="ref">8</xref>, <xref rid="jdv14542-bib-0009" ref-type="ref">9</xref>
</p></sec></sec><sec id="jdv14542-sec-0012"><title>Results</title><sec id="jdv14542-sec-0013"><title>Patient demographics and disposition</title><p>Two&#x02010;hundred and thirty patients with laBCC (<italic>n</italic>&#x000a0;=&#x000a0;194) or mBCC (<italic>n</italic>&#x000a0;=&#x000a0;36) were enrolled between 20 July 2011 and 10 January 2013. Patients were randomized to sonidegib 200&#x000a0;mg (laBCC, <italic>n</italic>&#x000a0;=&#x000a0;66; mBCC, <italic>n</italic>&#x000a0;=&#x000a0;13) or 800&#x000a0;mg (laBCC, <italic>n</italic>&#x000a0;=&#x000a0;128; mBCC, <italic>n</italic>&#x000a0;=&#x000a0;23; Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S1</xref>, Supporting Information). Baseline demographics were well balanced between arms.<xref rid="jdv14542-bib-0008" ref-type="ref">8</xref>, <xref rid="jdv14542-bib-0009" ref-type="ref">9</xref> Most patients with laBCC (200&#x000a0;mg, 56.1%; 800&#x000a0;mg, 58.6%) had aggressive tumour histology. By the data cut&#x02010;off for the 18&#x02010;month analysis (median follow&#x02010;up, 26.3&#x000a0;months), 87.0% of patients (200&#x000a0;mg, 86.1%; 800&#x000a0;mg, 87.4%) had discontinued treatment; by the data cut&#x02010;off for the 30&#x02010;month analysis (median follow&#x02010;up, 38.2&#x000a0;months), 93.0% (200&#x000a0;mg, 92.4%; 800&#x000a0;mg, 93.4%) had discontinued treatment (Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S1</xref>, Supporting Information). The most common reasons for treatment discontinuation were AEs [30&#x02010;month analysis (200 vs. 800&#x000a0;mg), 29.1% vs. 37.7%], progressive disease (36.7% vs. 14.6%) and patient decision (10.1% vs. 21.9%).</p></sec><sec id="jdv14542-sec-0014"><title>Efficacy in patients with laBCC</title><p>ORRs in patients with laBCC increased compared with the primary analysis (Table&#x000a0;<xref rid="jdv14542-tbl-0001" ref-type="table-wrap">1</xref>; Table&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S2</xref>, Supporting Information). Tumour shrinkage was observed in most patients (Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S2</xref>, Supporting Information). In the 30&#x02010;month analysis, ORRs in the 200&#x02010;mg arm were 56.1% (central review) and 71.2% (investigator review); in the 800&#x02010;mg arm, ORRs were 45.3% and 58.6%, respectively. Per central review, 26 of 37 patients with laBCC in the 200&#x02010;mg arm who achieved an objective response by the 30&#x02010;month data cut&#x02010;off maintained the response (Fig.&#x000a0;<xref rid="jdv14542-fig-0001" ref-type="fig">1</xref>a; Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S3</xref>a, Supporting Information), and the estimated median DOR in the 200&#x02010;mg arm was 26.1&#x000a0;months (15.7&#x000a0;months per investigator review). Among patients with laBCC who responded to treatment in the 800&#x02010;mg arm, 38 of 58 maintained an objective response per central review (Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S3</xref>b, Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S4</xref>a, Supporting Information), and the estimated median DOR was 23.7&#x000a0;months (26.0&#x000a0;months per investigator review). At the 30&#x02010;month data cut&#x02010;off, the median durations of PFS among patients with laBCC were 22.1&#x000a0;months (central review) and 19.4&#x000a0;months (investigator review) in the 200&#x02010;mg arm (Fig.&#x000a0;<xref rid="jdv14542-fig-0001" ref-type="fig">1</xref>b) and 22.0 and 28.0&#x000a0;months, respectively, in the 800&#x02010;mg arm (Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S4</xref>b, Supporting Information).</p><table-wrap id="jdv14542-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Efficacy in patients with laBCC treated with sonidegib 200&#x000a0;mg by central and investigator review</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Patients with laBCC</th><th align="left" colspan="5" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Sonidegib 200&#x000a0;mg QD</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1"/><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Primary analysis<xref ref-type="fn" rid="jdv14542-note-0005">a</xref>
</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">18&#x02010;month analysis<xref ref-type="fn" rid="jdv14542-note-0006">b</xref>
</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">30&#x02010;month analysis<xref ref-type="fn" rid="jdv14542-note-0007">c</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">All patients <italic>n</italic>&#x000a0;=&#x000a0;66</th><th align="left" valign="top" rowspan="1" colspan="1">All patients <italic>n</italic>&#x000a0;=&#x000a0;66</th><th align="left" valign="top" rowspan="1" colspan="1">All patients <italic>n</italic>&#x000a0;=&#x000a0;66</th><th align="left" valign="top" rowspan="1" colspan="1">Patients with aggressive histology<xref ref-type="fn" rid="jdv14542-note-0008">d</xref>
<italic>n</italic>&#x000a0;=&#x000a0;37</th><th align="left" valign="top" rowspan="1" colspan="1">Patients with non&#x02010;aggressive histology<xref ref-type="fn" rid="jdv14542-note-0009">e</xref>
<italic>n</italic>&#x000a0;=&#x000a0;29</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">ORR, <italic>n</italic> (%); 95% CI<xref ref-type="fn" rid="jdv14542-note-0010">f</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">31 (47.0); 34.6&#x02013;59.7</td><td align="left" rowspan="1" colspan="1">37 (56.1); 43.3&#x02013;68.3</td><td align="left" rowspan="1" colspan="1">37 (56.1); 43.3&#x02013;68.3</td><td align="left" rowspan="1" colspan="1">22 (59.5); 42.1&#x02013;75.2</td><td align="left" rowspan="1" colspan="1">15 (51.7); 32.5&#x02013;70.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">43 (65.2); 52.4&#x02013;76.5</td><td align="left" rowspan="1" colspan="1">47 (71.2); 58.7&#x02013;81.7</td><td align="left" rowspan="1" colspan="1">47 (71.2); 58.7&#x02013;81.7</td><td align="left" rowspan="1" colspan="1">26 (70.3); 53.0&#x02013;84.1</td><td align="left" rowspan="1" colspan="1">21 (72.4); 52.8&#x02013;87.3</td></tr><tr><td align="left" colspan="6" rowspan="1">BOR, <italic>n</italic> (%)<xref ref-type="fn" rid="jdv14542-note-0011">g</xref>
</td></tr><tr><td align="left" style="padding-left:10%" colspan="6" rowspan="1">CR</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">2 (3.0)</td><td align="left" rowspan="1" colspan="1">3 (4.5)</td><td align="left" rowspan="1" colspan="1">3 (4.5)</td><td align="left" rowspan="1" colspan="1">2 (5.4)</td><td align="left" rowspan="1" colspan="1">1 (3.4)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">5 (7.6)</td><td align="left" rowspan="1" colspan="1">6 (9.1)</td><td align="left" rowspan="1" colspan="1">6 (9.1)</td><td align="left" rowspan="1" colspan="1">3 (8.1)</td><td align="left" rowspan="1" colspan="1">3 (10.3)</td></tr><tr><td align="left" style="padding-left:10%" colspan="6" rowspan="1">PR</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">29 (43.9)</td><td align="left" rowspan="1" colspan="1">34 (51.5)</td><td align="left" rowspan="1" colspan="1">34 (51.5)</td><td align="left" rowspan="1" colspan="1">20 (54.1)</td><td align="left" rowspan="1" colspan="1">14 (48.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">38 (57.6)</td><td align="left" rowspan="1" colspan="1">41 (62.1)</td><td align="left" rowspan="1" colspan="1">41 (62.1)</td><td align="left" rowspan="1" colspan="1">23 (62.2)</td><td align="left" rowspan="1" colspan="1">18 (62.1)</td></tr><tr><td align="left" style="padding-left:10%" colspan="6" rowspan="1">SD</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">29 (43.9)</td><td align="left" rowspan="1" colspan="1">23 (34.8)</td><td align="left" rowspan="1" colspan="1">23 (34.8)</td><td align="left" rowspan="1" colspan="1">12 (32.4)</td><td align="left" rowspan="1" colspan="1">11 (37.9)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">16 (24.2)</td><td align="left" rowspan="1" colspan="1">14 (21.2)</td><td align="left" rowspan="1" colspan="1">13 (19.7)</td><td align="left" rowspan="1" colspan="1">8 (21.6)</td><td align="left" rowspan="1" colspan="1">5 (17.2)</td></tr><tr><td align="left" style="padding-left:10%" colspan="6" rowspan="1">PD</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">1 (1.5)</td><td align="left" rowspan="1" colspan="1">1 (1.5)</td><td align="left" rowspan="1" colspan="1">1 (1.5)</td><td align="left" rowspan="1" colspan="1">1 (2.7)</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">1 (1.5)</td><td align="left" rowspan="1" colspan="1">1 (1.5)</td><td align="left" rowspan="1" colspan="1">1 (1.5)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (3.4)</td></tr><tr><td align="left" style="padding-left:10%" colspan="6" rowspan="1">Unknown</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">5 (7.6)</td><td align="left" rowspan="1" colspan="1">5 (7.6)</td><td align="left" rowspan="1" colspan="1">5 (7.6)</td><td align="left" rowspan="1" colspan="1">2 (5.4)</td><td align="left" rowspan="1" colspan="1">3 (10.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">6 (9.1)</td><td align="left" rowspan="1" colspan="1">4 (6.1)</td><td align="left" rowspan="1" colspan="1">5 (7.6)</td><td align="left" rowspan="1" colspan="1">3 (8.1)</td><td align="left" rowspan="1" colspan="1">2 (6.9)</td></tr><tr><td align="left" colspan="6" rowspan="1">DOR<xref ref-type="fn" rid="jdv14542-note-0012">h</xref>
</td></tr><tr><td align="left" colspan="6" rowspan="1">
Events<xref ref-type="fn" rid="jdv14542-note-0013">i</xref>/responders, <italic>n</italic>/<italic>n</italic>;<break/>
KM median (95% CI), months
</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">4/31; NR</td><td align="left" rowspan="1" colspan="1">10/37; NR</td><td align="left" rowspan="1" colspan="1">11/37; 26.1 (NE)</td><td align="left" rowspan="1" colspan="1">7/22; 26.1 (NE)</td><td align="left" rowspan="1" colspan="1">4/15; NR</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">10/43; 20.2 (10.1&#x02013;20.2)</td><td align="left" rowspan="1" colspan="1">21/47; 14.3 (12.0&#x02013;20.2)</td><td align="left" rowspan="1" colspan="1">22/47; 15.7 (12.0&#x02013;20.2)</td><td align="left" rowspan="1" colspan="1">9/26; 20.2 (NE)</td><td align="left" rowspan="1" colspan="1">13/21; 15.7 (11.0&#x02013;20.2)</td></tr><tr><td align="left" colspan="6" rowspan="1">PFS<xref ref-type="fn" rid="jdv14542-note-0014">j</xref>
</td></tr><tr><td align="left" colspan="6" rowspan="1">Events<xref ref-type="fn" rid="jdv14542-note-0013">i</xref>, <italic>n</italic>; KM median (95% CI), months</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">7; NR</td><td align="left" rowspan="1" colspan="1">15; 22.1 (NE)</td><td align="left" rowspan="1" colspan="1">16; 22.1 (NE)</td><td align="left" rowspan="1" colspan="1">11; 22.1 (NE)</td><td align="left" rowspan="1" colspan="1">5; NR</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">15; 16.6 (13.7&#x02013;22.0)</td><td align="left" rowspan="1" colspan="1">26; 19.4 (16.6&#x02013;22.6)</td><td align="left" rowspan="1" colspan="1">28; 19.4 (16.6&#x02013;23.6)</td><td align="left" rowspan="1" colspan="1">12; 19.0 (NE)</td><td align="left" rowspan="1" colspan="1">16; 19.4 (9.2&#x02013;22.6)</td></tr><tr><td align="left" colspan="6" rowspan="1">OS<xref ref-type="fn" rid="jdv14542-note-0015">k</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Deaths, <italic>n</italic>; KM median (95% CI), months</td><td align="left" rowspan="1" colspan="1">1; NR</td><td align="left" rowspan="1" colspan="1">3; NR</td><td align="left" rowspan="1" colspan="1">5; NR</td><td align="left" rowspan="1" colspan="1">4; NR</td><td align="left" rowspan="1" colspan="1">1; NR</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x02010;year OS (95% CI), %</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">93.2 (80.2&#x02013;97.8)</td><td align="left" rowspan="1" colspan="1">91.8 (70.9&#x02013;97.9)</td><td align="left" rowspan="1" colspan="1">94.7 (68.1&#x02013;99.2)</td></tr></tbody></table><table-wrap-foot><fn id="jdv14542-note-0004"><p>BOR, best overall response; CR, complete response; DOR, duration of response; KM, Kaplan&#x02013;Meier; laBCC, locally advanced basal cell carcinoma; NE, not estimable; NR, not reached; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression&#x02010;free survival; PR, partial response; QD, once daily; SD, stable disease; &#x02013;, indicates not reported.</p></fn><fn id="jdv14542-note-0005"><label>a</label><p>Data cut&#x02010;off, 28 June 2013; median follow&#x02010;up (200&#x02010; and 800&#x02010;mg arms), 13.9&#x000a0;months.</p></fn><fn id="jdv14542-note-0006"><label>b</label><p>Data cut&#x02010;off, 11 July 2014; median follow&#x02010;up (200&#x02010; and 800&#x02010;mg arms), 26.3&#x000a0;months.</p></fn><fn id="jdv14542-note-0007"><label>c</label><p>Data cut&#x02010;off, 10 July 2015; median follow&#x02010;up (200&#x02010; and 800&#x02010;mg arms), 38.2&#x000a0;months.</p></fn><fn id="jdv14542-note-0008"><label>d</label><p>Aggressive histological subtypes of BCC include micronodular, infiltrative, multifocal, basosquamous and sclerosing.</p></fn><fn id="jdv14542-note-0009"><label>e</label><p>Non&#x02010;aggressive histological subtypes of BCC include nodular and superficial.</p></fn><fn id="jdv14542-note-0010"><label>f</label><p>Proportion of patients with a BOR of CR or PR on repeat assessments &#x02265;4&#x000a0;weeks apart.</p></fn><fn id="jdv14542-note-0011"><label>g</label><p>Best response recorded from the time of randomization until the earliest occurrence of disease progression, start of other antineoplastic therapy or data cut&#x02010;off date.</p></fn><fn id="jdv14542-note-0012"><label>h</label><p>Time from first observed objective response (CR or PR) until disease progression or death due to any cause (responder data only).</p></fn><fn id="jdv14542-note-0013"><label>i</label><p>Progressive disease or death due to any cause.</p></fn><fn id="jdv14542-note-0014"><label>j</label><p>Time from randomization to first documented disease progression or death due to any cause.</p></fn><fn id="jdv14542-note-0015"><label>k</label><p>Time from randomization to the date of death due to any cause or the last date the patient was known to be alive.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="jdv14542-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Duration of response (DOR) in patients with locally advanced basal cell carcinoma (laBCC) and progression&#x02010;free survival (PFS) by central and investigator review in patients with laBCC or metastatic BCC (mBCC) treated with sonidegib 200&#x000a0;mg. (a) Kaplan&#x02013;Meier plots of DOR in patients with laBCC who responded to treatment with sonidegib 200&#x000a0;mg per central (<italic>n</italic>&#x000a0;=&#x000a0;37) and investigator (<italic>n</italic>&#x000a0;=&#x000a0;47) review. (b) Kaplan&#x02013;Meier plots of PFS in patients with laBCC (<italic>n</italic>&#x000a0;=&#x000a0;66) and mBCC (<italic>n</italic>&#x000a0;=&#x000a0;13) treated with sonidegib 200&#x000a0;mg per central and investigator review.</p></caption><graphic id="nlm-graphic-1" xlink:href="JDV-32-372-g001"/></fig><p>Response in patients with laBCC was also assessed using BCC&#x02010;RECIST&#x02013;like criteria. Although ORRs and DORs were similar with both sets of criteria, CR rates were higher with BCC&#x02010;RECIST&#x02010;like criteria (Table&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S3</xref>, Supporting Information). In the 200&#x02010;mg arm, CR rates in the 30&#x02010;month analysis per central review were 21.2% (BCC&#x02010;RECIST&#x02010;like) vs. 4.5% (mRECIST).</p><p>Efficacy was similar among patients with laBCC with aggressive or non&#x02010;aggressive histological subtypes. In the 30&#x02010;month analysis, ORRs in patients with aggressive vs. non&#x02010;aggressive histology in the 200&#x02010;mg arm were 59.5% vs. 51.7% per central review and 70.3% vs. 72.4% per investigator review (Table&#x000a0;<xref rid="jdv14542-tbl-0001" ref-type="table-wrap">1</xref>); respective ORRs in the 800&#x02010;mg arm were 44.0% vs. 47.2% per central review and 54.7% vs. 64.2% per investigator review (Table&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S2</xref>, Supporting Information). Tumour responses were durable regardless of tumour aggressiveness.</p><p>At the time of the 18&#x02010;month analysis, efficacy in patients with laBCC was also assessed based on tumour burden at baseline. Responses were found to be durable regardless of tumour burden with both doses, with &#x0003e;58% of patients in each group having responses lasting &#x0003e;6&#x000a0;months (Table&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S4</xref>, Supporting Information).</p><p>Five patients with laBCC in the 200&#x02010;mg arm died by the 30&#x02010;month analysis; median OS was not yet reached and the estimated 2&#x02010;year OS was 93.2% (Table&#x000a0;<xref rid="jdv14542-tbl-0001" ref-type="table-wrap">1</xref>; Fig.&#x000a0;<xref rid="jdv14542-fig-0002" ref-type="fig">2</xref>). In the 800&#x02010;mg arm, 11 patients with laBCC died; median OS was not reached and the estimated 2&#x02010;year OS was 90.7% (Table&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S2</xref>, Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S5</xref>, Supporting Information). Numerically more deaths were reported in patients with aggressive (200&#x000a0;mg, 4; 800&#x000a0;mg, 8) vs. non&#x02010;aggressive (200&#x000a0;mg, 1; 800&#x000a0;mg, 3) histology; median OS was not reached in either population with either dose, and 2&#x02010;year OS rates were 91.8% vs. 94.7% (200&#x000a0;mg) and 86.6% vs. 95.8% (800&#x000a0;mg).</p><fig fig-type="Figure" xml:lang="en" id="jdv14542-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Overall survival (OS) in patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC) treated with sonidegib 200&#x000a0;mg. Kaplan&#x02013;Meier plot of OS in patients with laBCC (<italic>n</italic>&#x000a0;=&#x000a0;66) or mBCC (<italic>n</italic>&#x000a0;=&#x000a0;13) treated with sonidegib 200&#x000a0;mg. NE, not estimable.</p></caption><graphic id="nlm-graphic-3" xlink:href="JDV-32-372-g002"/></fig></sec><sec id="jdv14542-sec-0015"><title>Efficacy in patients with mBCC</title><p>Tumour shrinkage was reported in most patients with mBCC (Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S6</xref>, Supporting Information). ORRs in the 200&#x02010;mg arm were 7.7% (central review) and 23.1% (investigator review) in the 30&#x02010;month analysis, and estimated median DOR was 24.0&#x000a0;months (central review) and 18.1&#x000a0;months (investigator review; Table&#x000a0;<xref rid="jdv14542-tbl-0002" ref-type="table-wrap">2</xref>). ORRs in the 800&#x02010;mg arm were 17.4% (central review) and 34.8% (investigator review); estimated median DOR was not reached per central review and was 10.2&#x000a0;months per investigator review (Table&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S5</xref>, Supporting Information). The disease control rate (CR&#x000a0;+&#x000a0;PR&#x000a0;+&#x000a0;stable disease) was high with sonidegib 200&#x000a0;mg (central, 92.3%; investigator, 84.6%) and 800&#x000a0;mg (central, 91.3%; investigator, 82.6%). The median PFS with sonidegib 200&#x000a0;mg was 13.1&#x000a0;months per central and investigator review (Fig.&#x000a0;<xref rid="jdv14542-fig-0001" ref-type="fig">1</xref>b) and with sonidegib 800&#x000a0;mg was 11.1&#x000a0;months per central review and 14.3&#x000a0;months per investigator review (Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S4</xref>b, Supporting Information).</p><table-wrap id="jdv14542-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Efficacy in patients with mBCC treated with sonidegib 200&#x000a0;mg by central and investigator review</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Patients with mBCC</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Sonidegib 200&#x000a0;mg QD <italic>n</italic>&#x000a0;=&#x000a0;13</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Primary analysis<xref ref-type="fn" rid="jdv14542-note-0017">a</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">18&#x02010;month analysis<xref ref-type="fn" rid="jdv14542-note-0018">b</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">30&#x02010;month analysis<xref ref-type="fn" rid="jdv14542-note-0019">c</xref>
</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">ORR, <italic>n</italic> (%); 95% CI<xref ref-type="fn" rid="jdv14542-note-0020">d</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">2 (15.4); 1.9&#x02013;45.4</td><td align="left" rowspan="1" colspan="1">1 (7.7)<xref ref-type="fn" rid="jdv14542-note-0021">e</xref>; 0.2&#x02013;36.0</td><td align="left" rowspan="1" colspan="1">1 (7.7); 0.2&#x02013;36.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">3 (23.1); 5.0&#x02013;53.8</td><td align="left" rowspan="1" colspan="1">3 (23.1); 5.0&#x02013;53.8</td><td align="left" rowspan="1" colspan="1">3 (23.1); 5.0&#x02013;53.8</td></tr><tr><td align="left" colspan="4" rowspan="1">BOR, <italic>n</italic> (%)<xref ref-type="fn" rid="jdv14542-note-0022">f</xref>
</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">CR</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">PR</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">2 (15.4)</td><td align="left" rowspan="1" colspan="1">1 (7.7)<xref ref-type="fn" rid="jdv14542-note-0021">e</xref>
</td><td align="left" rowspan="1" colspan="1">1 (7.7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">3 (23.1)</td><td align="left" rowspan="1" colspan="1">3 (23.1)</td><td align="left" rowspan="1" colspan="1">3 (23.1)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">SD</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">10 (76.9)</td><td align="left" rowspan="1" colspan="1">11 (84.6)</td><td align="left" rowspan="1" colspan="1">11 (84.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">8 (61.5)</td><td align="left" rowspan="1" colspan="1">8 (61.5)</td><td align="left" rowspan="1" colspan="1">8 (61.5)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">PD</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">2 (15.4)</td><td align="left" rowspan="1" colspan="1">2 (15.4)</td><td align="left" rowspan="1" colspan="1">2 (15.4)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Unknown</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">1 (7.7)</td><td align="left" rowspan="1" colspan="1">1 (7.7)</td><td align="left" rowspan="1" colspan="1">1 (7.7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="4" rowspan="1">DOR<xref ref-type="fn" rid="jdv14542-note-0023">g</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">
Events/responders, <italic>n</italic>/<italic>n</italic>
<xref ref-type="fn" rid="jdv14542-note-0024">h</xref>;<break/>
KM median (95% CI), months
</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">0/2; NR</td><td align="left" rowspan="1" colspan="1">0/1; NR</td><td align="left" rowspan="1" colspan="1">1/1; 24.0 (NE)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">0/3; NR</td><td align="left" rowspan="1" colspan="1">1/3; 17.7 (NE)</td><td align="left" rowspan="1" colspan="1">2/3; 18.1 (17.7&#x02013;18.4)</td></tr><tr><td align="left" colspan="4" rowspan="1">PFS<xref ref-type="fn" rid="jdv14542-note-0025">i</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Events, <italic>n</italic>; KM median (95% CI), months<xref ref-type="fn" rid="jdv14542-note-0024">h</xref>
</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Central review</td><td align="left" rowspan="1" colspan="1">4; 13.1 (5.6&#x02013;13.1)</td><td align="left" rowspan="1" colspan="1">6; 13.1 (NE)</td><td align="left" rowspan="1" colspan="1">8; 13.1 (5.6&#x02013;33.1)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Investigator review</td><td align="left" rowspan="1" colspan="1">7; 13.1 (9.2&#x02013;16.6)</td><td align="left" rowspan="1" colspan="1">8; 13.1 (NE)</td><td align="left" rowspan="1" colspan="1">9; 13.1 (9.2&#x02013;19.4)</td></tr><tr><td align="left" colspan="4" rowspan="1">OS<xref ref-type="fn" rid="jdv14542-note-0026">j</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Deaths, <italic>n</italic>; KM median (95% CI), months</td><td align="left" rowspan="1" colspan="1">1; NR</td><td align="left" rowspan="1" colspan="1">3; NR</td><td align="left" rowspan="1" colspan="1">3; NR</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x02010;year OS (95% CI), %</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">69.3 (31.2&#x02013;89.1)</td></tr></tbody></table><table-wrap-foot><fn id="jdv14542-note-0016"><p>BOR, best overall response; CR, complete response; DOR, duration of response; KM, Kaplan&#x02013;Meier; mBCC, metastatic basal cell carcinoma; NE, not estimable; NR, not reached; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression&#x02010;free survival; PR, partial response; QD, once daily; SD, stable disease; &#x02013;, indicates not reported.</p></fn><fn id="jdv14542-note-0017"><label>a</label><p>Data cut&#x02010;off, 28 June 2013; median follow&#x02010;up (200&#x02010; and 800&#x02010;mg arms), 13.9&#x000a0;months.</p></fn><fn id="jdv14542-note-0018"><label>b</label><p>Data cut&#x02010;off, 11 July 2014; median follow&#x02010;up (200&#x02010; and 800&#x02010;mg arms), 26.3&#x000a0;months.</p></fn><fn id="jdv14542-note-0019"><label>c</label><p>Data cut&#x02010;off, 10 July 2015; median follow&#x02010;up (200&#x02010; and 800&#x02010;mg arms), 38.2&#x000a0;months.</p></fn><fn id="jdv14542-note-0020"><label>d</label><p>Proportion of patients with a BOR of CR or PR on repeat assessments &#x02265;4&#x000a0;weeks apart.</p></fn><fn id="jdv14542-note-0021"><label>e</label><p>BOR of one patient changed from a PR to SD due to identification of a new lesion by central rereview in a photograph received after the cut&#x02010;off for the primary analysis (28 June 2013).</p></fn><fn id="jdv14542-note-0022"><label>f</label><p>Best response recorded from the time of randomization until the earliest occurrence of disease progression, start of other antineoplastic therapy or data cut&#x02010;off date.</p></fn><fn id="jdv14542-note-0023"><label>g</label><p>Time from first observed objective response (CR or PR) until disease progression or death due to any cause (responder data only).</p></fn><fn id="jdv14542-note-0024"><label>h</label><p>Progressive disease or death due to any cause.</p></fn><fn id="jdv14542-note-0025"><label>i</label><p>Time from randomization to first documented disease progression or death due to any cause.</p></fn><fn id="jdv14542-note-0026"><label>j</label><p>Time from randomization to the date of death due to any cause or the last date the patient was known to be alive.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>In the 30&#x02010;month analysis, 11 patients (200&#x000a0;mg, 3; 800&#x000a0;mg, 8) with mBCC had died. With sonidegib 200&#x000a0;mg, the estimated median OS was not reached, and the estimated 2&#x02010;year OS was 69.3% (Fig.&#x000a0;<xref rid="jdv14542-fig-0002" ref-type="fig">2</xref>). With sonidegib 800&#x000a0;mg, the estimated median OS was 36.7&#x000a0;months, and the estimated 2&#x02010;year OS was 69.1% (Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S5</xref>, Supporting Information).</p></sec><sec id="jdv14542-sec-0016"><title>Sonidegib PK</title><p>Sonidegib PK was evaluated based on the 18&#x02010;month data cut&#x02010;off (by which time all patients had completed the scheduled PK assessments). Mean sonidegib plasma concentrations rose until week &#x02248;13&#x02013;17 with daily 200 and 800&#x000a0;mg dosing (Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S7</xref>, Supporting Information). By week 17, an approximate steady state was reached for both doses. Sonidegib demonstrated under dose&#x02010;proportional increases in plasma exposure between the two doses tested: at week 17, the geometric mean trough concentration was 689&#x000a0;ng/mL with 200&#x000a0;mg and 1574&#x000a0;ng/mL with 800&#x000a0;mg, corresponding to a &#x02248;2.3&#x02010;fold increase in trough concentration over a fourfold dose increase.</p></sec><sec id="jdv14542-sec-0017"><title>Safety</title><p>No new safety concerns emerged with an additional 24&#x000a0;months of follow&#x02010;up since the primary analysis. At the 30&#x02010;month data cut&#x02010;off, the median duration of exposure was 11.0&#x000a0;months (range, 1.3&#x02013;41.3&#x000a0;months) in the 200&#x02010;mg arm and 6.6&#x000a0;months (range, 0.3&#x02013;43.5&#x000a0;months) in the 800&#x02010;mg arm. The incidence of many of the most common AEs was lower with sonidegib 200&#x000a0;mg than 800&#x000a0;mg, including muscle spasms, alopecia, dysgeusia, nausea, weight decreased, creatine kinase (CK) increased, fatigue, appetite decreased, myalgia and vomiting (Fig.&#x000a0;<xref rid="jdv14542-fig-0003" ref-type="fig">3</xref>). The most common AEs reported in patients with laBCC (Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S8</xref>, Supporting Information) and mBCC (Fig.&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S9</xref>, Supporting Information) were similar. Among all patients, grade 3/4 AEs occurred less frequently with sonidegib 200&#x000a0;mg (43.0%) than with 800&#x000a0;mg (64.0%); similar results were reported for grade 3/4 AEs suspected to be related to treatment, with a lower incidence in the 200&#x02010;mg arm (30.4%) than the 800&#x02010;mg arm (43.3%). Increased CK was the most common grade 3/4 AE (10.9%; 200&#x000a0;mg, 6.3%; 800&#x000a0;mg, 13.3%); only one additional patient (800&#x000a0;mg) had a grade 3/4 increase in CK after the primary analysis cut&#x02010;off. The median time to onset (range) of grade 2/3/4 CK elevation was 12.9 (2&#x02013;39) and 6.7 (2&#x02013;40) weeks in the 200&#x02010; and 800&#x02010;mg arms, respectively; the median time to resolution (95% CI) to grade &#x02264;1 was 12.0 (8.0&#x02013;14.0) and 15.0 (9.0&#x02013;15.0)&#x000a0;days, respectively.</p><fig fig-type="Figure" xml:lang="en" id="jdv14542-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Adverse events (AEs), regardless of causality, reported in &#x02265;20% of all patients treated with sonidegib, by treatment arm. The most common AEs reported in patients treated with sonidegib 200&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;79) or 800&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;150) assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events v4.03.<xref rid="jdv14542-bib-0020" ref-type="ref">20</xref> Reported AEs include those that occurred during treatment and within 30&#x000a0;days of treatment discontinuation. For a patient who had multiple occurrences of the same AE, the AE is reported only once at the highest severity rating. CK, creatine kinase; laBCC, locally advanced basal cell carcinoma; mBCC, metastatic BCC.</p></caption><graphic id="nlm-graphic-5" xlink:href="JDV-32-372-g003"/></fig><p>AEs requiring dose interruption and/or reduction were reported in 43.0% and 66.7% of patients in the 200&#x02010; and 800&#x02010;mg arms, respectively; the most common AEs leading to dose interruption/reduction (200&#x000a0;mg vs. 800&#x000a0;mg) were muscle spasms (1.3% vs. 16.7%), CK increased (6.3% vs. 12.0%), and nausea (6.3% vs. 12.0%). AEs leading to treatment discontinuation also occurred less frequently with the 200&#x02010;mg dose (30.4%) than the 800&#x02010;mg dose (40.0%), with most (60.7%; 200&#x000a0;mg, 54.2%; 800&#x000a0;mg, 63.3%) being grade 1/2. The most common AEs leading to discontinuation (200&#x000a0;mg vs. 800&#x000a0;mg) were muscle spasms (5.1% vs. 8.0%), weight decreased (2.5% vs. 6.0%), dysgeusia (3.8% vs. 4.7%) and alopecia (1.3% vs. 6.0%).</p><p>Serious AEs (SAEs) irrespective of cause were reported in 20.3% and 38.7% of patients treated with sonidegib 200&#x000a0;mg and 800&#x000a0;mg, respectively (Table&#x000a0;<xref rid="jdv14542-sup-0001" ref-type="supplementary-material">S6</xref>, Supporting Information); SAEs related to sonidegib treatment occurred in 3.8% and 16.0%, respectively. Increased CK and rhabdomyolysis were the most commonly reported SAEs among all patients (2.6% each; 200&#x000a0;mg, 1.3% each; 800&#x000a0;mg, 3.3% each); due to a lack of renal impairment, none of the cases of rhabdomyolysis were confirmed by an independent review and adjudication committee of experts on muscle toxicity.<xref rid="jdv14542-bib-0008" ref-type="ref">8</xref>
</p><p>On&#x02010;treatment deaths were reported in eight patients (200&#x000a0;mg, 1; 800&#x000a0;mg, 7), four of whom had laBCC (200&#x000a0;mg, 1; 800&#x000a0;mg, 3) and four had mBCC (800&#x000a0;mg, 4); none of these deaths were considered treatment related. Four on&#x02010;treatment deaths [two due to progressive disease (both with mBCC) and one each due to congestive cardiac failure (laBCC) and cardiac death (laBCC)] were reported in the primary analysis,<xref rid="jdv14542-bib-0008" ref-type="ref">8</xref> and four occurred following the primary analysis, including one patient treated with sonidegib 200&#x000a0;mg (laBCC) who died of acute respiratory distress on study day 612, and three patients treated with 800&#x000a0;mg who died of cardiac arrest (laBCC), sepsis (mBCC) and respiratory arrest (mBCC) on study days 349, 391 and 433, respectively.</p></sec></sec><sec id="jdv14542-sec-0018"><title>Discussion</title><p>With long&#x02010;term follow&#x02010;up in BOLT, sonidegib 200 and 800&#x000a0;mg continued to demonstrate sustained efficacy in patients with laBCC (regardless of histology) and mBCC. Since the time of the primary analysis, ORRs in the 200&#x02010;mg arm improved in patients with laBCC and remained similar in patients with mBCC. Higher rates of response were observed by investigator vs. central review, which could be due to investigators having the opportunity to physically examine lesions that are often complicated by post&#x02010;treatment ulceration, cyst formation, scarring/fibrosis and ill&#x02010;defined borders.<xref rid="jdv14542-bib-0008" ref-type="ref">8</xref> Responses in patients with laBCC were durable regardless of tumour burden at baseline, with most patients (central, 70.3%; investigator, 53.2%) who responded to treatment with sonidegib 200&#x000a0;mg maintaining an objective response at the 30&#x02010;month data cut&#x02010;off. Moreover, when responses in patients with laBCC were scored using less&#x02010;stringent response criteria (BCC&#x02010;RECIST&#x02010;like criteria, similar to criteria used in ERIVANCE<xref rid="jdv14542-bib-0011" ref-type="ref">11</xref>), CR rates were similar to those reported with vismodegib in ERIVANCE.<xref rid="jdv14542-bib-0012" ref-type="ref">12</xref> This analysis underscores the efficacy of sonidegib in patients with laBCC. However, efficacy in patients with disease that recurred following prior HPI therapy is unknown because these patients were excluded from BOLT.</p><p>The rate of survival in patients with BCC is extremely high<xref rid="jdv14542-bib-0021" ref-type="ref">21</xref>, <xref rid="jdv14542-bib-0022" ref-type="ref">22</xref>; however, the prognosis for patients with advanced BCC is less clear.<sup>1</sup> In patients with laBCC, the survival rate is unknown due in part to a lack of reporting of these data in patient registries. In patients with mBCC, the median survival prior to 1990 was estimated to be &#x02248; 8&#x000a0;months and recently has been estimated to be as high as &#x02248; 7&#x000a0;years due to improved therapies, including HPIs.<xref rid="jdv14542-bib-0023" ref-type="ref">23</xref>, <xref rid="jdv14542-bib-0024" ref-type="ref">24</xref>, <xref rid="jdv14542-bib-0025" ref-type="ref">25</xref> In BOLT, the median OS in patients with laBCC was not reached with either dose by the 30&#x02010;month analysis, and the estimated 2&#x02010;year OS was &#x0003e;90% in both arms; in patients with mBCC, the median OS was not yet reached with sonidegib 200&#x000a0;mg and was 36.7&#x000a0;months with 800&#x000a0;mg, and the estimated 2&#x02010;year OS was &#x02248; 69% in both arms. These survival rates are similar to those reported with vismodegib [85.5% (laBCC) and 62.3% (mBCC) at 2&#x000a0;years in ERIVANCE], the only other approved HPI.<xref rid="jdv14542-bib-0013" ref-type="ref">13</xref>
</p><p>The PK of sonidegib is different from that of vismodegib. Vismodegib exposure did not increase above the 150&#x02010;mg daily dosage due to saturated protein binding, and the half&#x02010;life was 4&#x000a0;days after repeated dosing.<xref rid="jdv14542-bib-0026" ref-type="ref">26</xref>, <xref rid="jdv14542-bib-0027" ref-type="ref">27</xref> In contrast, sonidegib exposure increased 2.3&#x02010;fold between 200 and 800&#x000a0;mg and reached an approximate steady state at &#x02248;17&#x000a0;weeks. Previously, PK exposure&#x02013;response and exposure&#x02013;safety analyses including the 200&#x02010; and 800&#x02010;mg doses (based on the 18&#x02010;month data cut&#x02010;off) showed no exposure&#x02013;efficacy relationship but a reduced risk of grade 3/4 CK elevation with lower exposure, further supporting the favourable benefit&#x02013;risk profile of sonidegib 200&#x000a0;mg vs. 800&#x000a0;mg.<xref rid="jdv14542-bib-0028" ref-type="ref">28</xref> Additionally, in a population PK model, sonidegib had a predicted elimination half&#x02010;life of 29.6&#x000a0;days and an accumulation ratio of 21.<xref rid="jdv14542-bib-0029" ref-type="ref">29</xref>
</p><p>Sonidegib 200&#x000a0;mg continued to be better tolerated than sonidegib 800&#x000a0;mg, and no additional safety concerns were reported with either dose. Lower incidences of grade 3/4 AEs, SAEs and AEs leading to discontinuation were observed with 200&#x000a0;mg vs. 800&#x000a0;mg. The majority of the most common AEs were generally grade 1 or 2 and were similar to those reported with other HPIs<xref rid="jdv14542-bib-0010" ref-type="ref">10</xref>, <xref rid="jdv14542-bib-0011" ref-type="ref">11</xref>, <xref rid="jdv14542-bib-0012" ref-type="ref">12</xref>, <xref rid="jdv14542-bib-0030" ref-type="ref">30</xref>, <xref rid="jdv14542-bib-0031" ref-type="ref">31</xref>, <xref rid="jdv14542-bib-0032" ref-type="ref">32</xref>, <xref rid="jdv14542-bib-0033" ref-type="ref">33</xref>, <xref rid="jdv14542-bib-0034" ref-type="ref">34</xref>, <xref rid="jdv14542-bib-0035" ref-type="ref">35</xref>, <xref rid="jdv14542-bib-0036" ref-type="ref">36</xref>, <xref rid="jdv14542-bib-0037" ref-type="ref">37</xref>, <xref rid="jdv14542-bib-0038" ref-type="ref">38</xref>, <xref rid="jdv14542-bib-0039" ref-type="ref">39</xref>; muscle&#x02010;related AEs and the increase in CK that can accompany these AEs are thought to be a class effect of HPIs.<xref rid="jdv14542-bib-0011" ref-type="ref">11</xref>, <xref rid="jdv14542-bib-0012" ref-type="ref">12</xref>, <xref rid="jdv14542-bib-0030" ref-type="ref">30</xref>, <xref rid="jdv14542-bib-0031" ref-type="ref">31</xref>, <xref rid="jdv14542-bib-0035" ref-type="ref">35</xref>, <xref rid="jdv14542-bib-0039" ref-type="ref">39</xref> Muscle&#x02010;related AEs were effectively managed with dose adjustments or interruptions. In the future, patients who experience sonidegib&#x02010;related AEs will be managed using this approach in an attempt to prolong exposure and enhance treatment benefit. In addition, future clinical trials designed to optimize the treatment regimen of HPIs may further improve outcomes.</p><p>Overall, these results support the use of sonidegib 200&#x000a0;mg as a treatment option for patients with advanced BCC according to local guidelines.<xref rid="jdv14542-bib-0014" ref-type="ref">14</xref>, <xref rid="jdv14542-bib-0015" ref-type="ref">15</xref>, <xref rid="jdv14542-bib-0016" ref-type="ref">16</xref>, <xref rid="jdv14542-bib-0017" ref-type="ref">17</xref>
</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="jdv14542-sup-0001"><caption><p>
<bold>Table&#x000a0;S1.</bold> Composite overall response in locally advanced basal cell carcinoma (laBCC) determined by mRECIST and BCC&#x02010;RECIST&#x02010;like criteria</p><p>
<bold>Table&#x000a0;S2.</bold> Efficacy in patients with locally advanced basal cell carcinoma (laBCC) treated with sonidegib 800&#x000a0;mg by central and investigator review</p><p>
<bold>Table&#x000a0;S3.</bold> Efficacy in patients with locally advanced basal cell carcinoma (laBCC) by central and investigator review per BCC&#x02010;recist&#x02010;like criteria (30&#x02010;month analysis)</p><p>
<bold>Table&#x000a0;S4.</bold> Efficacy in patients with locally advanced basal cell carcinoma (laBCC) by baseline tumor burden by treatment arm (18&#x02010;month analysis)</p><p>
<bold>Table&#x000a0;S5.</bold> Efficacy in patients with metastatic basal cell carcinoma (mBCC) treated With Sonidegib 800 mg by central and investigator review</p><p>
<bold>Table&#x000a0;S6.</bold> Serious adverse events reported in &#x02265;1% of patients in either arm, regardless of causality (30&#x02010;month analysis)</p><p>
<bold>Figure&#x000a0;S1.</bold> BOLT trial profile.</p><p>
<bold>Figure&#x000a0;S2.</bold> Waterfall plots of best change from baseline in the size of target lesions in patients with locally advanced basal cell carcinoma (laBCC).</p><p>
<bold>Figure&#x000a0;S3.</bold> Duration of response (DOR) in patients with locally advanced basal cell carcinoma (laBCC).</p><p>
<bold>Figure&#x000a0;S4.</bold> Kaplan&#x02013;Meier plots of duration of response (DOR) in patients with locally advanced basal cell carcinoma (laBCC) and of progression&#x02010;free survival (PFS) in patients with laBCC and metastatic BCC (mBCC) treated with sonidegib 800&#x000a0;mg by central and investigator review.</p><p>
<bold>Figure&#x000a0;S5.</bold> Kaplan&#x02013;Meier plot of overall survival (OS) in patients with locally advanced basal cell carcinoma (laBCC) and metastatic BCC (mBCC) treated with sonidegib 800&#x000a0;mg.</p><p>
<bold>Figure&#x000a0;S6.</bold> Waterfall plots of best change from baseline in the size of target lesions in patients with metastatic basal cell carcinoma (mBCC).</p><p>
<bold>Figure&#x000a0;S7.</bold> Mean trough&#x02010;concentration time profiles for sonidegib 200 or 800&#x000a0;mg.</p><p>
<bold>Figure&#x000a0;S8.</bold> Adverse events (AEs), regardless of causality, reported in &#x02265;20% of patients with locally advanced basal cell carcinoma (laBCC) treated with sonidegib, by treatment arm.</p><p>
<bold>Figure&#x000a0;S9.</bold> Adverse events (AEs), regardless of causality, reported in &#x02265;20% of patients with metastatic basal cell carcinoma (mBCC) treated with sonidegib, by treatment arm.</p></caption><media xlink:href="JDV-32-372-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="jdv14542-sec-0019"><title>Acknowledgements</title><p>We thank the patients and their families, the study investigators, their clinical teams and the study site staff, and the members of the study committees. We also thank the Novartis BOLT clinical study team, Yi Wu of Novartis for statistical support, the independent data monitoring committee (Mark R. Pittelkow, J&#x000fc;rgen C. Becker and Stephen L. George), the efficacy independent review (Vernon K. Sondak, James Grichnik and Lawrence Schwartz), and the muscle safety review and adjudication committee (Robert S. Rosenson, Vinay Chaudhry and Paul D. Thompson). Medical editorial assistance was provided by Karen Kaluza, PhD (ArticulateScience LLC) and funded by Novartis Pharmaceuticals Corporation.</p></ack><ref-list content-type="cited-references" id="jdv14542-bibl-0001"><title>References</title><ref id="jdv14542-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jdv14542-cit-0001">
<string-name>
<surname>Lear</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Corner</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dziewulski</surname>
<given-names>P</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective</article-title>. <source>Br J Cancer</source>
<year>2014</year>; <volume>111</volume>: <fpage>1476</fpage>&#x02013;<lpage>1481</lpage>.<pub-id pub-id-type="pmid">25211660</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jdv14542-cit-0002">
<string-name>
<surname>Wong</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Strange</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Lear</surname>
<given-names>JT</given-names>
</string-name>. <article-title>Basal cell carcinoma</article-title>. <source>BMJ</source>
<year>2003</year>; <volume>327</volume>: <fpage>794</fpage>&#x02013;<lpage>798</lpage>.<pub-id pub-id-type="pmid">14525881</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jdv14542-cit-0003">
<string-name>
<surname>Madan</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Lear</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Szeimies</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Non&#x02010;melanoma skin cancer</article-title>. <source>Lancet</source>
<year>2010</year>; <volume>375</volume>: <fpage>673</fpage>&#x02013;<lpage>685</lpage>.<pub-id pub-id-type="pmid">20171403</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jdv14542-cit-0004">
<string-name>
<surname>Gupta</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takebe</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Lorusso</surname>
<given-names>P</given-names>
</string-name>. <article-title>Targeting the Hedgehog pathway in cancer</article-title>. <source>Ther Adv Med Oncol</source>
<year>2010</year>; <volume>2</volume>: <fpage>237</fpage>&#x02013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">21789137</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jdv14542-cit-0005">
<string-name>
<surname>Reifenberger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wolter</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Knobbe</surname>
<given-names>CB</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas</article-title>. <source>Br J Dermatol</source>
<year>2005</year>; <volume>152</volume>: <fpage>43</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">15656799</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jdv14542-cit-0006">
<string-name>
<surname>Pan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>J</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Discovery of NVP&#x02010;LDE225, a potent and selective smoothened antagonist</article-title>. <source>ACS Med Chem Lett</source>
<year>2010</year>; <volume>1</volume>: <fpage>130</fpage>&#x02013;<lpage>134</lpage>.<pub-id pub-id-type="pmid">24900187</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jdv14542-cit-0007">
<string-name>
<surname>Rodon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tawbi</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>AL</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>A phase I, multicenter, open&#x02010;label, first&#x02010;in&#x02010;human, dose&#x02010;escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors</article-title>. <source>Clin Cancer Res</source>
<year>2014</year>; <volume>20</volume>: <fpage>1900</fpage>&#x02013;<lpage>1909</lpage>.<pub-id pub-id-type="pmid">24523439</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jdv14542-cit-0008">
<string-name>
<surname>Migden</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Guminski</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gutzmer</surname>
<given-names>R</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double&#x02010;blind phase 2 trial</article-title>. <source>Lancet Oncol</source>
<year>2015</year>; <volume>16</volume>: <fpage>716</fpage>&#x02013;<lpage>728</lpage>.<pub-id pub-id-type="pmid">25981810</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jdv14542-cit-0009">
<string-name>
<surname>Dummer</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Guminski</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gutzmer</surname>
<given-names>R</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>The 12&#x02010;month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): a phase II, randomized, double&#x02010;blind study of sonidegib in patients with advanced basal cell carcinoma</article-title>. <source>J Am Acad Dermatol</source>
<year>2016</year>; <volume>75</volume>: <fpage>113</fpage>&#x02013;<lpage>125</lpage>.<pub-id pub-id-type="pmid">27067394</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jdv14542-cit-0010">
<string-name>
<surname>Lorusso</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Rudin</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Reddy</surname>
<given-names>JC</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Phase I trial of hedgehog pathway inhibitor GDC&#x02010;0449 in patients with refractory, locally advanced or metastatic solid tumors</article-title>. <source>Clin Cancer Res</source>
<year>2011</year>; <volume>17</volume>: <fpage>2502</fpage>&#x02013;<lpage>2511</lpage>.<pub-id pub-id-type="pmid">21300762</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jdv14542-cit-0011">
<string-name>
<surname>Sekulic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Migden</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Oro</surname>
<given-names>AE</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Efficacy and safety of vismodegib in advanced basal&#x02010;cell carcinoma</article-title>. <source>N Engl J Med</source>
<year>2012</year>; <volume>366</volume>: <fpage>2171</fpage>&#x02013;<lpage>2179</lpage>.<pub-id pub-id-type="pmid">22670903</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jdv14542-cit-0012">
<string-name>
<surname>Sekulic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Migden</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>K</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12&#x02010;month update of efficacy and safety of vismodegib in advanced BCC</article-title>. <source>J Am Acad Dermatol</source>
<year>2015</year>; <volume>72</volume>: <fpage>1021</fpage>&#x02013;<lpage>1026</lpage>. e8<pub-id pub-id-type="pmid">25981002</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jdv14542-cit-0013">
<string-name>
<surname>Sekulic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Migden</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Basset&#x02010;Seguin</surname>
<given-names>N</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Long&#x02010;term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update (30&#x02010;month) of the pivotal ERIVANCE BCC study</article-title>. <source>J Clin Oncol</source>
<year>2014</year>; <volume>32</volume>: <fpage>9013</fpage>.</mixed-citation></ref><ref id="jdv14542-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="jdv14542-cit-0014">
<collab collab-type="authors">Novartis Pharmaceuticals Corporation</collab>
. <article-title>Odomzo (sonidegib) Prescribing Information</article-title>. <year>2016</year> URL <ext-link ext-link-type="uri" xlink:href="https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/odomzo.pdf">https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/odomzo.pdf</ext-link> (last accessed: 28 September 2016).</mixed-citation></ref><ref id="jdv14542-bib-0015"><label>15</label><mixed-citation publication-type="miscellaneous" id="jdv14542-cit-0015">
<collab collab-type="authors">European Medicines Agency: Committee for Medicinal Products for Human Use</collab>
. <article-title>CHMP summary of opinion for Odomzo</article-title>. <year>2015</year> URL <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002839/WC500188762.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002839/WC500188762.pdf</ext-link> (last accessed: 28 September 2016).</mixed-citation></ref><ref id="jdv14542-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="jdv14542-cit-0016">
<collab collab-type="authors">Swissmedic authorized medicines</collab>
. <article-title>Swissmedic authorization of Odomzo</article-title>. <year>2015</year> URL <ext-link ext-link-type="uri" xlink:href="https://www.swissmedic.ch/arzneimittel/00156/00221/00222/00230/index.html?lang=en">https://www.swissmedic.ch/arzneimittel/00156/00221/00222/00230/index.html?lang=en</ext-link> (last accessed: 28 September 2016).</mixed-citation></ref><ref id="jdv14542-bib-0017"><label>17</label><mixed-citation publication-type="miscellaneous" id="jdv14542-cit-0017">
<collab collab-type="authors">Australian Government</collab>
. Department of Health and Ageing: Therapeutic Goods Administration. <article-title>Australian public assessment report for Odomzo</article-title>, <year>2015</year>.</mixed-citation></ref><ref id="jdv14542-bib-0018"><label>18</label><mixed-citation publication-type="book" id="jdv14542-cit-0018">
<collab collab-type="authors">World Health Organization</collab>
. <source>WHO Handbook for Reporting Results for Cancer Treatment</source>. <publisher-name>World Health Organization</publisher-name>, <publisher-loc>Geneva</publisher-loc>, <year>1979</year>.</mixed-citation></ref><ref id="jdv14542-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jdv14542-cit-0019">
<string-name>
<surname>Eisenhauer</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Therasse</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bogaerts</surname>
<given-names>J</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title>. <source>Eur J Cancer</source>
<year>2009</year>; <volume>45</volume>: <fpage>228</fpage>&#x02013;<lpage>247</lpage>.<pub-id pub-id-type="pmid">19097774</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0020"><label>20</label><mixed-citation publication-type="miscellaneous" id="jdv14542-cit-0020">
<collab collab-type="authors">US Department of Health and Human Services</collab>
. National Cancer Institute. <article-title>Common terminology criteria for adverse events (CTCAE) version 4.03</article-title>, <year>2010</year> URL <ext-link ext-link-type="uri" xlink:href="https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf">https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf</ext-link> (last accessed: 28 September 2016)</mixed-citation></ref><ref id="jdv14542-bib-0021"><label>21</label><mixed-citation publication-type="miscellaneous" id="jdv14542-cit-0021">
<collab collab-type="authors">American Cancer Society</collab>
. <article-title>Basal and squamous cell skin cancers</article-title>, <year>2016</year> URL <ext-link ext-link-type="uri" xlink:href="https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer.html">https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer.html</ext-link> (last accessed: 28 September 2016).</mixed-citation></ref><ref id="jdv14542-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="jdv14542-cit-0022">
<collab collab-type="authors">National Cancer Institute</collab>
. <article-title>Skin cancer treatment (PDQ&#x000ae;)&#x02013;health professional version</article-title>, <year>2016</year> URL <ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/types/skin/hp/skin-treatment-pdq">https://www.cancer.gov/types/skin/hp/skin-treatment-pdq</ext-link> (last accessed: 28 September 2016).</mixed-citation></ref><ref id="jdv14542-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jdv14542-cit-0023">
<string-name>
<surname>von Domarus</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Stevens</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature</article-title>. <source>J Am Acad Dermatol</source>
<year>1984</year>; <volume>10</volume>: <fpage>1043</fpage>&#x02013;<lpage>1060</lpage>.<pub-id pub-id-type="pmid">6736323</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jdv14542-cit-0024">
<string-name>
<surname>Raszewski</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Guyuron</surname>
<given-names>B</given-names>
</string-name>. <article-title>Long&#x02010;term survival following nodal metastases from basal cell carcinoma</article-title>. <source>Ann Plast Surg</source>
<year>1990</year>; <volume>24</volume>: <fpage>170</fpage>&#x02013;<lpage>175</lpage>.<pub-id pub-id-type="pmid">2180360</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jdv14542-cit-0025">
<string-name>
<surname>Danial</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lingala</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Balise</surname>
<given-names>R</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma</article-title>. <source>Br J Dermatol</source>
<year>2013</year>; <volume>169</volume>: <fpage>673</fpage>&#x02013;<lpage>676</lpage>.<pub-id pub-id-type="pmid">23521172</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jdv14542-cit-0026">
<string-name>
<surname>Lorusso</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Jimeno</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dy</surname>
<given-names>G</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Pharmacokinetic dose&#x02010;scheduling study of hedgehog pathway inhibitor vismodegib (GDC&#x02010;0449) in patients with locally advanced or metastatic solid tumors</article-title>. <source>Clin Cancer Res</source>
<year>2011</year>; <volume>17</volume>: <fpage>5774</fpage>&#x02013;<lpage>5782</lpage>.<pub-id pub-id-type="pmid">21753154</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0027"><label>27</label><mixed-citation publication-type="miscellaneous" id="jdv14542-cit-0027">
<collab collab-type="authors">Genentech, Inc</collab>
. <article-title>Erivedge (vismodegib) prescribing information</article-title>, <year>2012</year> URL <ext-link ext-link-type="uri" xlink:href="https://www.gene.com/download/pdf/erivedge_prescribing.pdf">https://www.gene.com/download/pdf/erivedge_prescribing.pdf</ext-link> (last accessed: 28 September 2016).</mixed-citation></ref><ref id="jdv14542-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jdv14542-cit-0028">
<string-name>
<surname>Zhou</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Quinlan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hurh</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sellami</surname>
<given-names>D</given-names>
</string-name>. <article-title>Exposure&#x02010;response analysis of sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for effectiveness and safety in patients with advanced solid tumors</article-title>. <source>J Clin Pharmacol</source>
<year>2016</year>; <volume>56</volume>: <fpage>1406</fpage>&#x02013;<lpage>1415</lpage>.<pub-id pub-id-type="pmid">27095306</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jdv14542-cit-0029">
<string-name>
<surname>Goel</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Hurh</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>A</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors</article-title>. <source>Cancer Chemother Phramacol</source>
<year>2016</year>; <volume>77</volume>: <fpage>745</fpage>&#x02013;<lpage>755</lpage>.</mixed-citation></ref><ref id="jdv14542-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jdv14542-cit-0030">
<string-name>
<surname>Basset&#x02010;Seguin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hauschild</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Grob</surname>
<given-names>JJ</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre&#x02010;planned interim analysis of an international, open&#x02010;label trial</article-title>. <source>Lancet Oncol</source>
<year>2015</year>; <volume>16</volume>: <fpage>729</fpage>&#x02013;<lpage>736</lpage>.<pub-id pub-id-type="pmid">25981813</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jdv14542-cit-0031">
<string-name>
<surname>Chang</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Solomon</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Hainsworth</surname>
<given-names>JD</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib</article-title>. <source>J Am Acad Dermatol</source>
<year>2013</year>; <volume>70</volume>: <fpage>60</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">24189279</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jdv14542-cit-0032">
<string-name>
<surname>Gajjar</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Gururangan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Qaddoumi</surname>
<given-names>IA</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): a Pediatric Brain Tumor Consortium study (PBTC 25B) [abstract]</article-title>. <source>J Clin Oncol</source>
<year>2013</year>; <volume>31</volume>: <fpage>2035</fpage>.</mixed-citation></ref><ref id="jdv14542-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jdv14542-cit-0033">
<string-name>
<surname>Goldman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Eckhardt</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Borad</surname>
<given-names>MJ</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Phase 1 Dose&#x02010;escalation trial of the oral investigational hedgehog signaling pathway inhibitor TAK&#x02010;441 in patients with advanced solid tumors</article-title>. <source>Clin Cancer Res</source>
<year>2014</year>; <volume>21</volume>: <fpage>1002</fpage>&#x02013;<lpage>1009</lpage>.<pub-id pub-id-type="pmid">25501576</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jdv14542-cit-0034">
<string-name>
<surname>Italiano</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Le Cesne</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bellera</surname>
<given-names>C</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>GDC&#x02010;0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single&#x02010;Arm Phase II Collaborative Study</article-title>. <source>Ann Oncol</source>
<year>2013</year>; <volume>24</volume>: <fpage>2922</fpage>&#x02013;<lpage>2926</lpage>.<pub-id pub-id-type="pmid">24170610</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jdv14542-cit-0035">
<string-name>
<surname>Jimeno</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>WH</given-names>
<suffix>Jr</suffix>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Phase I study of the hedgehog pathway inhibitor IPI&#x02010;926 in adult patients with solid tumors</article-title>. <source>Clin Cancer Res</source>
<year>2013</year>; <volume>19</volume>: <fpage>2766</fpage>&#x02013;<lpage>2774</lpage>.<pub-id pub-id-type="pmid">23575478</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jdv14542-cit-0036">
<string-name>
<surname>Siu</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Papadopoulos</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Alberts</surname>
<given-names>SR</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>A first&#x02010;in&#x02010;human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS&#x02010;833923 (XL139), in subjects with advanced or metastatic solid tumors [abstract]</article-title>. <source>J Clin Oncol</source>
<year>2010</year>; <volume>28</volume>: <fpage>2501</fpage>.</mixed-citation></ref><ref id="jdv14542-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jdv14542-cit-0037">
<string-name>
<surname>Tang</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Mackay&#x02010;Wiggan</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Aszterbaum</surname>
<given-names>M</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Inhibiting the hedgehog pathway in patients with the basal&#x02010;cell nevus syndrome</article-title>. <source>N Engl J Med</source>
<year>2012</year>; <volume>366</volume>: <fpage>2180</fpage>&#x02013;<lpage>2188</lpage>.<pub-id pub-id-type="pmid">22670904</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jdv14542-cit-0038">
<string-name>
<surname>Wagner</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Messersmith</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Shaik</surname>
<given-names>MN</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>A phase I study of PF&#x02010;04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors</article-title>. <source>Clin Cancer Res</source>
<year>2015</year>; <volume>21</volume>: <fpage>1044</fpage>&#x02013;<lpage>1051</lpage>.<pub-id pub-id-type="pmid">25388167</pub-id></mixed-citation></ref><ref id="jdv14542-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jdv14542-cit-0039">
<string-name>
<surname>Ally</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Aasi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wysong</surname>
<given-names>A</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>An investigator&#x02010;initiated open&#x02010;label clinical trial of vismodegib as a neoadjuvant to surgery for high&#x02010;risk basal cell carcinoma</article-title>. <source>J Am Acad Dermatol</source>
<year>2014</year>; <volume>71</volume>: <fpage>904</fpage>&#x02013;<lpage>911</lpage>.<pub-id pub-id-type="pmid">24929884</pub-id></mixed-citation></ref></ref-list></back></article>